Nivolumab for the Treatment of Patients with Metastatic Non‐Clear Cell Renal Cell Carcinoma (nccRCC): A Single‐Institutional Experience and Literature Meta‐Analysis

INTRODUCTION: Nivolumab alone and in combination with ipilimumab is approved for the treatment of patients with metastatic renal cell carcinoma (RCC) who received prior vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR‐TKI) and those who are treatment naive, respectively....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Chahoud, Jad, Msaouel, Pavlos, Campbell, Matthew T., Bathala, Tharakeswara, Xiao, Lianchun, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Yogesh, Jonasch, Eric, Sharma, Padmanee, Tannir, Nizar M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Genitourinary Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066696/
https://ncbi.nlm.nih.gov/pubmed/32162795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0372
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados